[{"indications": "Indications\u00a0prophylaxis against hepatitis B infection", "name": "HEPATITIS B IMMUNOGLOBULIN For intramuscular use", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "14 Immunological products and vaccines", "14.5 Immunoglobulins", "14.5.2 Disease-specific immunoglobulins", "Hepatitis B", "HEPATITIS B IMMUNOGLOBULIN", "For intramuscular use"], "cautions": "Cautions\u00a0IgA deficiency; interference with live virus vaccines see under Normal Immunoglobulin.", "side-effects": "Side-effects\u00a0injection site reactions; less frequently, buccal\r\nulceration, glossitis, abdominal pain, chest pain, dyspnoea, anaphylaxis,\r\ntremor, dizziness, headache, arthralgia; for side-effects associated\r\nwith intravenous immunoglobulin, see section 14.5.1", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/6547.htm", "doses": ["See under preparations and see also notes above", "Prevention of transmitted infection at birth, neonate 200\u00a0units as soon as possible after birth;\r\nfor full details consult Immunisation against Infectious Disease (www.dh.gov.uk)", "Name[Hepatitis B Immunoglobulin ] Injection, hepatitis B-specific\r\nimmunoglobulin, 100\u00a0units/mL. Vials containing 200\u00a0units or 500\u00a0units,\r\navailable from selected Health Protection Agency and NHS laboratories\r\n(except for Transplant Centres, see section 14.5 under Availability), also available from BPLDose\u00a0by intramuscular injection (as soon as\r\npossible after exposure; ideally within 12\u201348 hours, but no later\r\nthan 7 days after exposure), adult and child over 10 years 500\u00a0units; child under 5 years 200\u00a0units, 5\u20139 years 300\u00a0units; neonate 200\u00a0unitsPrevention of transmitted infection at birth, neonate 200\u00a0units as soon as possible after birth;\r\nfor full details consult Immunisation against Infectious Disease (www.dh.gov.uk)"]}, {"indications": "Indications\u00a0prophylaxis against hepatitis B infection", "name": "HEPATITIS B IMMUNOGLOBULIN For intravenous use", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "14 Immunological products and vaccines", "14.5 Immunoglobulins", "14.5.2 Disease-specific immunoglobulins", "Hepatitis B", "HEPATITIS B IMMUNOGLOBULIN", "For intravenous use"], "cautions": "Cautions\u00a0IgA deficiency; interference with live virus vaccines see under Normal Immunoglobulin.", "side-effects": "Side-effects\u00a0injection site reactions; less frequently, buccal\r\nulceration, glossitis, abdominal pain, chest pain, dyspnoea, anaphylaxis,\r\ntremor, dizziness, headache, arthralgia; for side-effects associated\r\nwith intravenous immunoglobulin, see section 14.5.1", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/202711.htm", "doses": ["See under preparations and see also notes above", "Prevention of transmitted infection at birth\u2014consult product\r\nliterature", "Name[Hepatect\u00aeCP (Biotest UK) ] Intravenous infusion, hepatitis\r\nB-specific immunoglobulin 50\u00a0units/mL, net price 500\u00a0units (10\u00a0mL)\r\n=  \u00a3300.00, 2000\u00a0units (40\u00a0mL) =  \u00a31100.00Dose\u00a0by intravenous infusion, after exposure\r\nto hepatitis B virus-contaminated material\u2014consult product literaturePrevention of transmitted infection at birth\u2014consult product\r\nliteraturePrevention of hepatitis B in haemodialysed patients, prophylaxis\r\nagainst re-infection of transplanted liver\u2014consult product literature"]}, {"indications": "Indications\u00a0prophylaxis against hepatitis B infection", "name": "HEPATITIS B IMMUNOGLOBULIN", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "14 Immunological products and vaccines", "14.5 Immunoglobulins", "14.5.2 Disease-specific immunoglobulins", "Hepatitis B", "HEPATITIS B IMMUNOGLOBULIN"], "cautions": "Cautions\u00a0IgA deficiency; interference with live virus vaccines see under Normal Immunoglobulin.", "side-effects": "Side-effects\u00a0injection site reactions; less frequently, buccal\r\nulceration, glossitis, abdominal pain, chest pain, dyspnoea, anaphylaxis,\r\ntremor, dizziness, headache, arthralgia; for side-effects associated\r\nwith intravenous immunoglobulin, see section 14.5.1", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/213807.htm", "doses": ["See under preparations and see also notes above"]}, {"indications": "Indications\u00a0prophylaxis against hepatitis B infection", "name": "HEPATITIS B IMMUNOGLOBULIN For subcutaneous use", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "14 Immunological products and vaccines", "14.5 Immunoglobulins", "14.5.2 Disease-specific immunoglobulins", "Hepatitis B", "HEPATITIS B IMMUNOGLOBULIN", "For subcutaneous use"], "cautions": "Cautions\u00a0IgA deficiency; interference with live virus vaccines see under Normal Immunoglobulin.", "side-effects": "Side-effects\u00a0injection site reactions; less frequently, buccal\r\nulceration, glossitis, abdominal pain, chest pain, dyspnoea, anaphylaxis,\r\ntremor, dizziness, headache, arthralgia; for side-effects associated\r\nwith intravenous immunoglobulin, see section 14.5.1", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/213808.htm", "doses": ["See under preparations and see also notes above", "Name[Zutectra\u00ae (Biotest UK)  ] Injection, hepatitis B-specific\r\nimmunoglobulin, 500\u00a0units/mL, net price 5 \u00d7 1-mL prefilled syringes\r\n= \u00a31500.00Dose\u00a0prevention of hepatitis B re-infection more than 6 months\r\nafter liver transplantation in stable HBV-DNA negative patients starting\r\n2\u20133 weeks after last dose of intravenous hepatitis B immunoglobulin, by subcutaneous injection, adult body-weight under 75\u00a0kg 500\u00a0units once weekly, increased if necessary\r\nup to 1000\u00a0units once weekly; body-weight over 75\u00a0kg 1000\u00a0units once\r\nweekly"]}, {"indications": "Indications\u00a0immunisation against hepatitis B infection", "name": "HEPATITIS B VACCINE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "14 Immunological products and vaccines", "14.4 Vaccines and antisera", "Hepatitis B vaccine", "HEPATITIS B VACCINE"], "cautions": "Cautions\u00a0see section 14.1", "side-effects": "Side-effects\u00a0see section 14.1", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/60021.htm", "doses": ["See under preparations"], "pregnancy": "Pregnancy\u00a0see section 14.1"}, {"indications": "Indications\u00a0immunisation against hepatitis B infection", "name": "HEPATITIS B VACCINE Single component", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "14 Immunological products and vaccines", "14.4 Vaccines and antisera", "Hepatitis B vaccine", "HEPATITIS B VACCINE", "Single component"], "cautions": "Cautions\u00a0see section 14.1", "side-effects": "Side-effects\u00a0see section 14.1", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/129410.htm", "doses": ["See under preparations", "Name[Fendrix\u00ae (GSK) ] Injection, suspension of hepatitis\r\nB surface antigen (prepared from yeast cells by recombinant DNA technique)\r\n40\u00a0micrograms/mL adsorbed onto aluminium phosphate, net price 0.5-mL\r\nprefilled syringe = \u00a338.10Excipients  include traces of thiomersalDose\u00a0adult and child over 15 years with renal insufficiency (including\r\npre-haemodialysis and haemodialysis patients), by intramuscular\r\ninjection (see note below) 4 doses of 20\u00a0micrograms, the second\r\n1 month, the third 2 months and the fourth 6 months after the first\r\ndose; immunisation schedule and booster doses may need to be adjusted\r\nin those with low antibody concentration Note\u00a0Deltoid muscle is preferred site of injection;\r\nnot to be injected into the buttock (vaccine efficacy reduced)"], "pregnancy": "Pregnancy\u00a0see section 14.1"}]